Naloxona Accord (Naloxone Hydrochloride)

Naloxona Accord, an opioid antagonist, is used in clinical situations involving opioid toxicity.

• Opioid overdose: rapid reversal of life‑threatening respiratory depression.
• Opioid‑induced respiratory depression: restoration of normal breathing in emergency settings.
• Opioid anesthesia reversal: termination of sedation after procedural opioid use.

• Naloxona Accord contains naloxone hydrochloride, which binds competitively to mu, kappa and delta opioid receptors without activating them. By displacing opioid agonists from these sites, it rapidly reduces receptor stimulation, thereby reversing the central nervous system and respiratory depressant effects of opioids. The antagonistic action is immediate after intravenous administration, allowing restoration of ventilation, improvement of oxygenation and consciousness in overdose patients.

Naloxona Accord may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Sweating: increased perspiration.
• Tachycardia: elevated heart rate.
• Agitation: restlessness or anxiety.

Serious or Rare Side Effects

• Acute pulmonary edema: fluid accumulation in lungs.
• Seizures: convulsive episodes.
• Anaphylaxis: severe allergic reaction.

When using Naloxona Accord, several precautions should be observed to ensure patient safety and drug efficacy.

• Assess airway: confirm patency before administration.
• Monitor vital signs: observe respiratory rate, blood pressure and heart rate continuously.
• Anticipate withdrawal: be prepared for precipitated opioid withdrawal symptoms in dependent patients.
• Use cautiously in cardiovascular disease: rapid reversal may cause hypertension or arrhythmia.
• Adjust for pediatric patients: dosing and monitoring require special consideration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Naloxona Accord can interact with other medications, influencing its effectiveness or safety.

Major Interactions (Avoid)

• High‑dose opioid agonists: may diminish the reversal effect of naloxone.
• Mixed agonist‑antagonist opioids (e.g., buprenorphine): can precipitate severe withdrawal.

Moderate Interactions (Monitor Closely)

• Benzodiazepines: additive central nervous system depression may persist after opioid reversal.
• Tricyclic antidepressants: increased risk of seizures when combined with naloxone.
• Antihypertensive agents: naloxone‑induced hypertension may mask hypotensive therapy.